LAVAL, Quebec, Nov. 17, 2016 /CNW/ -- Valeant
Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX)
("Valeant") today learned that a criminal complaint was filed in
relation to Philidor. Gary
Tanner and Andrew Davenport
were charged in the matter. The company, former CEO, former CFO,
and current executives have not been charged at this time.
Gary Tanner ceased to be a Valeant
employee on September 13, 2015, and
Andrew Davenport has never been an
employee of the Company. The counts issued today include
allegations that the charged parties engaged in actions to defraud
Valeant as a company. Valeant continues to cooperate with all
relevant authorities in this matter.
About Valeant
Valeant Pharmaceuticals International,
Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical
company that develops, manufactures and markets a broad range of
pharmaceutical products primarily in the areas of dermatology,
gastrointestinal disorders, eye health, neurology and branded
generics. More information about Valeant can be found at
www.valeant.com.
Contact Information:
Elif McDonald
elif.mcdonald@valeant.com
514-856-3855
877-281-6642 (toll free)
Media:
Renée Soto
or
Chris Kittredge/Jared Levy
Sard Verbinnen & Co.
212-687-8080
Logo -
http://photos.prnewswire.com/prnh/20101025/LA87217LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/valeant-comments-on-issued-philidor-criminal-charges-300365174.html
SOURCE Valeant Pharmaceuticals International, Inc.